GlassScriptPhysician profile
Rhonda V Fleming
NPI 1376590067
$10,495.25
in general payments reported to CMS, 2019-2025
18 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,433 · 2020: $2,672 · 2021: $347 · 2022: $492 · 2023: $622 · 2024: $597 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Education: $69.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.38 |
| Education | $69.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,397.08 | 2019-2020 | |
| Viiv Healthcare Company | $1,123.29 | 2022-2025 | Cabenuva, Dovato, Apretude |
| Smith+Nephew, INC. | $419.50 | 2019-2024 | Collagenase Santyl |
| Organogenesis INC. | $247.73 | 2019-2024 | Affinity |
| Melinta Therapeutics, LLC | $220.29 | 2019-2025 | Rezzayo |
| Insmed, INC. | $206.03 | 2023-2025 | Arikayce |
| Astellas Pharma US INC | $133.99 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $122.51 | 2023 | Farxiga |
| Osiris Therapeutics INC. | $119.87 | 2019 | |
| Merck Sharp & Dohme LLC | $117.74 | 2019-2022 | |
| Solventum Corporation | $99.98 | 2024 | Activ.A.C. |
| Janssen Products, LP | $99.00 | 2021 | |
| Janssen Biotech, INC. | $70.84 | 2020-2021 | |
| Cardiovascular Systems INC. | $50.71 | 2021 | |
| La Jolla Pharmaceutical Company | $25.03 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.36 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $13.51 | 2020 | |
| Gilead Sciences, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.